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ARTICLE
Post-capillary venules are the key locus for
transcytosis-mediated brain delivery of therapeutic
nanoparticles
Krzysztof Kucharz 1,5✉, Kasper Kristensen 2,5, Kasper Bendix Johnsen2,5, Mette Aagaard Lund2,
Micael Lønstrup 1, Torben Moos3, Thomas Lars Andresen2 & Martin Johannes Lauritzen1,4✉
Effective treatments of neurodegenerative diseases require drugs to be actively transported
across the blood-brain barrier (BBB). However, nanoparticle drug carriers explored for this
purpose show negligible brain uptake, and the lack of basic understanding of nanoparticle-
BBB interactions underlies many translational failures. Here, using two-photon microscopy in
mice, we characterize the receptor-mediated transcytosis of nanoparticles at all steps of
delivery to the brain in vivo. We show that transferrin receptor-targeted liposome nano-
particles are sequestered by the endothelium at capillaries and venules, but not at arterioles.
The nanoparticles move unobstructed within endothelium, but transcytosis-mediated brain
entry occurs mainly at post-capillary venules, and is negligible in capillaries. The vascular
location of nanoparticle brain entry corresponds to the presence of perivascular space, which
facilitates nanoparticle movement after transcytosis. Thus, post-capillary venules are the
point-of-least resistance at the BBB, and compared to capillaries, provide a more feasible
route for nanoparticle drug carriers into the brain.
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The blood-brain barrier (BBB) is impermeable to mostblood-borne substances, protecting the fragile brainenvironment from potentially harmful insults1. The para-
cellular entry of molecules from the blood to the brain is barred
by junctional complexes between adjoining brain endothelial cells
(BEC)2. Diffusion of molecules across BECs is possible but
restricted to low-molecular-weight hydrophobic compounds.
Most of them, however, including therapeutics, show negligible
brain uptake due to rapid outward transport by efflux pumps to
the bloodstream3,4. Macromolecules, e.g., proteins, can enter the
brain by vesicular transport, i.e., transcytosis, but this route is
highly selective and actively suppressed by recently identified
homeostatic mechanisms5,6. Consequently, the BBB precludes
more than 99% of neuroprotective compounds from reaching the
brain, rendering central nervous system (CNS) disorders resistant
to most conventional therapies3,7,8.
Drug delivery systems that aim to adapt receptor-mediated
transcytosis (RMT) to shuttle therapeutic cargo across the BBB
are currently at the forefront of modern therapeutic approaches
against brain diseases9–11. The flagship ferrying receptor on BECs
used for that purpose is the transferrin receptor (TfR)8,12,13.
Neuroprotective compounds show enhanced brain delivery when
coupled to TfR ligands, e.g., antibody fragments14,15, but require
chemical conjugation to the targeting moiety. In comparison,
nanoparticle drug carriers are versatile delivery vehicles that can
encapsulate large payloads of xenobiotics with a wide range of
biophysical characteristics, offering diverse and unique ther-
apeutic opportunities9–11. Liposome nanoparticles functionalized
with TfR ligands represent a promising drug delivery approach
tested currently in preclinical trials in brain cancer, stroke, and
Parkinson’s, Alzheimer’s, and Huntington’s disease, but the levels
of nanoparticle transport into the brain need to improve to meet
dosage requirements and reach clinical significance12,13.
To improve drug delivery, it is crucial to understand how the
BBB handles drug nanocarriers in the living brain, but conven-
tional experimental techniques only provide limited mechanistic
insights. Whole-brain imaging techniques, such as PET or MRI,
are insufficient to resolve the spatio-temporal characteristics of
single nanocarrier-BBB interactions in vivo. Consequently, the
events between administration and detection of therapeutics in
the brain are obscured. Our current knowledge is extrapolated
from chemically processed tissue3,13,16, which erases all infor-
mation on the dynamic processes at the BBB. In addition, the
vessel microanatomy differs between arterioles, capillaries, and
venules17,18. This principal feature of the brain is overlooked in
drug delivery studies, and how it impacts drug delivery is
unknown.
Here, to address these issues, we used two-photon in vivo
imaging to examine how distinct types of cerebral vessels handle
drug nanocarriers in real-time, in the intact brain, in anesthetized
and awake mice. We characterized the pharmacokinetics of
nanoparticles targeted toward the TfR at the BBB, their intra-
cellular trafficking patterns in vascular BECs, and transcytosis-
mediated entry and transit in the brain parenchyma. We report
that TfR-targeted nanoparticles bind to BECs at venules and
capillaries but not at arterioles. Despite the highest association of
nanoparticles to BECs in capillaries, we found that the trafficking
to the brain occurs almost exclusively at post-capillary venules,
with a negligible contribution of capillaries. The vascular locus of
nanoparticle transport was consistent with the presence of peri-
vascular space around post-capillary venules, which facilitates the
movement of nanoparticle-sized elements in the CNS. These
observations provide insight into therapeutic nanoparticle traf-
ficking and delivery to the brain and challenge the assumed view
that capillaries are the hub for effective brain transport of
nanoparticle drug carriers. Thus, our findings prompt
reconsideration of nanoparticle targeting strategies for improved
drug delivery to the brain.
Results
Two-photon imaging of nanoparticles in vivo. To study BBB-
nanoparticles interactions in vivo, we used two-photon fluores-
cence microscopy. The brain was imaged via a cranial window
over the somatosensory cortex in mice (Fig. 1a, b). The liposome
nanoparticles were designed to resemble clinically approved
formulations19, i.e., consisted of a distearoylphosphatidylcholine
(DSPC)/cholesterol lipid bilayer surrounding an aqueous lumen,
with a polyethylene glycol (PEG) coating to ensure stability in the
blood (Fig. 1c, Supplementary Table 1). Targeting of the trans-
cytosis pathway in BECs was enabled by coupling high-affinity
anti-TfR antibodies (clone RI7217) to the nanoparticle surface20
—a targeting moiety that mediates a high level of nanoparticle
binding to the brain endothelium21,22.
Prior to imaging experiments, we validated the nanoparticle
formulation and targeting strategy by encapsulating the BBB-
impermeable drug cisplatin into the nanoparticles (Supplementary
Table 1). The brain uptake of cisplatin was measured using
inductively coupled plasma-mass spectrometry (ICP-MS)22, and at
2 h after intravenous (i.v.) injection of the nanoparticles, cisplatin was
detected in the brain only for nanoparticles functionalized with
RI7217, but not for stealth (no targeting antibody), or isotype IgG
antibodies (no TfR recognition) (Fig. 1d).
To study nanoparticle-BBB interactions in detail, in all
subsequent experiments, we utilized two-photon imaging. The
nanoparticle lipid bilayer was tagged with either Atto 550 or Atto
488 fluorophores (Fig. 1c). Both the Atto 550- and Atto 488-
labeled nanoparticles (RI7-L-A550 and RI7-L-A488) were admi-
nistered by single bolus injection into the bloodstream
(70 nmollipid/ganimal), and the imaging was performed in a
somatosensory cortex volume that contained all microvascular
segments, i.e., arterioles, venules, and capillaries (Fig. 1e).
Following the injection, the blood-circulating nanoparticles
exhibited high fluorescence stability over time, indicating a low
filtration rate by peripheral organs (Fig. 1f, g, Supplementary
Movie 1). A small fraction of nanoparticles was sequestered by
circulating leukocytes, but this did not inhibit the interaction of
the leukocytes with post-capillary venules (Supplementary
Fig. 1a–d, Supplementary Movie 2). Consistently, we observed
no detrimental effects of nanoparticles on the brain and systemic
physiology (Supplementary Fig. 1e; Supplementary Methods).
Nanoparticles that circulated in the bloodstream retained their
structural stability, as ascertained after laser-extravasation of
nanoparticles to the brain parenchyma, i.e., temporary opening of
the BBB by a short burst of the laser beam on the vessel wall
(duration= 2 s, area= ~1 µm2). The nanoparticles exhibited a
discrete single-particle appearance without signs of agglomeration
or fusion, even when extravasated after 3 h in circulation (Fig. 1h,
i). Both types of nanoparticles exhibited properties of a point
source signal with a Gaussian fluorescence distribution peak with
average standard deviation (σ) equal to 0.290 ± 0.006 µm and
0.296 ± 0.008 µm for RI7-L-A550 and RI7-L-A488 respectively,
which did not differ between distinctively labeled nanoparticles
(Fig. 1j). In subsequent experiments, the nanoparticles were
considered spatially separated from other sources of fluorescence
when their peaks were in the distance exceeding 2σ of their
fluorescence distribution profile. This distance satisfied the
Rayleigh separation criterion for optical microscopy, being larger
than the minimum resolved distance equaling 0.53 µm at
excitation λ= 870 nm and NAobjective= 1.
Thus, the nanoparticles fulfilled all necessary requirements for
in vivo imaging: efficient two-photon excitation and fluorescence
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Fig. 1 Two-photon imaging of liposome nanoparticles in vivo. a Schematic drawing of a mouse after the preparative surgery. b Mouse head with the
location of craniotomy and the main features of the cranial window. c Principal components of nanoparticles used in the study. d Nanoparticles
functionalized with RI7217 antibody drive accumulation of cisplatin payload in the brain, in contrast to nanoparticles with isotype IgGs, and nanoparticles
devoid of antibody (stealth). %ID/g is the percentage of the injected dose of nanoparticle-encapsulated cisplatin per gram brain tissue measured 2 h post
i.v. injection with ICP-MS; nstealth, IgG= 4 mice, nRI7217= 5 mice. e Brain somatosensory cortex volume imaged in the study. Example 3D reconstructions
show brain microvessels delineated by fluorescence of blood-circulating nanoparticles. f Hyperstack (Z-stack over time) images of fluorescence signal from
nanoparticles after injection into the bloodstream. Time is relative to the time of injection. Long panels are kymographs of fluorescence changes measured
from venules at demarked lines. ‘zs’ inset indicates Z-stack maximum intensity projection. See also Supplementary Movie 1. g Fluorescence from blood-
circulating RI7-L-A550 and RI7-L-A488 exhibit a relatively high degree of stability over time, being in the range of commonly used tracers in vascular
imaging studies, i.e., FITC- and TRITC-dextran. RI7-L-A550 and RI7-L-A488 signals were measured simultaneously with co-injected FITC- and TRITC-
dextran, respectively. Traces represent single animals with symbols matching individual mice between corresponding imaging channels. n= 3 mice in each
group. h Laser-extravasated nanoparticles into the brain parenchyma 3 h after injection into the circulation. Nanoparticles retain their discrete and
homogeneous appearance even after 3 h of circulation. i Laser-extravasated RI7-L-A488 and RI7-LA550 into the brain parenchyma 3 h after co-injection
into the circulation. Lack of merged fluorescence signal from nanoparticles indicates no liposome fusion or aggregation when in circulation or in the brain.
j The averages of nanoparticles fluorescence profile plots after laser-extravasation into the brain. The average standard deviations (σ) of Gaussian profiles
describing fluorescence signal distribution do not differ between distinctively labeled nanoparticles. n= 20 vs. 20 nanoparticles extravasated in 1 mouse
per nanoparticle type, p= 0.5910, two-tailed t-test. All panels: ns non-significant. Data are means ± SEM.
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emission, with the ability to resolve single nanoparticles, high
structural stability in the circulation, and no observable
detrimental effects on the brain and systemic physiology.
Targeted nanoparticles associate to capillaries and venules, but
not to arterioles. The first step of RMT is the recruitment of a
nanoparticle from the circulation to the luminal membrane of the
BECs. Since in vitro BBB models fail to reproduce other vessel
phenotypes than capillaries, we investigated whether TfR-targeted
nanoparticle recruitment differs between distinct vascular seg-
ments in vivo. The vessels were classified as pial arterioles,
penetrating arterioles, and capillaries using the anatomical fea-
tures, vessel orientation, and direction of the blood flow (Sup-
plementary Methods). In mice, the capillaries branch from ~10
µm lumen diameter vessels to reach an average ~<6 µm
diameter23,24, then converge into larger post-capillary venules
with diameter >6 µm25, that project to ascending venules or
directly to pial venules17. RI7-L-A550 nanoparticles were co-
injected into the bloodstream with 2 MDa FITC-dextran (FITC-
dx) to delineate the vessel lumen. At 2 h post-injection, nano-
particles were present as numerous punctae at the vessel walls of
the pial, ascending, and post-capillary venules, and capillaries
(Fig. 2a–e), but did not associate to the arterial branches of the
brain microvasculature (Fig. 2f). Next, we ascertained that a
nanoparticle targeting moiety, i.e., antibody, is necessary for a
circulating nanoparticle to be captured from the bloodstream at
the luminal side of the BECs. The association was driven by the
TfR-Ab binding to the TfR, and not by non-specific interactions
since neither antibody-lacking stealth nanoparticles (Sth-L-A550,
Supplementary Fig. 1f, g) nor isotype IgG-functionalized nano-
particles that lack TfR recognition associated to BECs (IgG-L-
A550, Supplementary Fig. 1h, i). Noteworthy, the association was
independent of the type of fluorescent tag, as RI7-L-A488
exhibited the same targeting properties as RI7-L-A550 (Supple-
mentary Fig. 2a–e). In addition, mice co-injected with both
nanoparticles exhibited distinct labeling at the same vessel walls
from both RI7-L-A550 and RI7-L-A488 nanoparticles, attesting
that the observed punctae represented single nanoparticles
(Fig. 2g). Scarce presence of merged signals was attributed to
overlapping fluorescence from nanoparticles separated by a dis-
tance smaller than the diffraction limit of the microscope
(Fig. 2h).
Vessel type determines nanoparticle association density and
kinetics. We then assessed whether there were differences in
nanoparticle distribution and association kinetics among vessels
that recruited nanoparticles from the bloodstream. BEC-
associated nanoparticles were separated from blood-circulating
nanoparticles by excluding the signal of circulating nanoparticles
that co-localized with FITC-dx in the vessel lumen (Fig. 3a).
Three-dimensional reconstructions revealed a spatially hetero-
geneous association of nanoparticles across the vascular interface
(Fig. 3b). At 2 h post-injection, the highest density of nano-
particles was at vessel walls of capillaries, with an exponential
decline along the post-capillary to pial venule axis (Fig. 3c). This
was consistent with the kinetics of association being fastest in
capillaries and slowest in pial venules (Fig. 3d, e, Supplementary
Fig. 2f–h, Supplementary Movie 3). Of note, nanoparticle binding
was ongoing even after 2 h post-injection, indicating that
regardless of the vessel type, the cellular pool of available TfRs
was not saturated at this time (Fig. 3e).
Most associated nanoparticles are internalized by the endo-
thelium. Association of a nanoparticle to the luminal side of the
vessel does not guarantee endocytosis into the BEC, and thus, the
ratio of adhering to internalized nanoparticles at the BEC is
informative to understand the uptake efficiency per immobilized
nanoparticle. Worth highlighting, in vivo two-photon imaging
provides an unbiased assessment of this ratio, compared to the
conventional histological analyses, which may impact the fraction
of luminally immobilized nanoparticles by direct washout, inter-
ference with receptor interaction, or by dissolving the lipid-
anchored fluorophore of the nanoparticle (Supplementary
Fig. 3a–c). We utilized transgenic mice expressing cytosolic green
fluorescent protein (GFP) in the endothelium (Tie2-GFP) to
ensure an anatomical setpoint for the analysis. This allowed for a
comprehensive assessment of the BEC morphology with sub-
cellular details in the living brain (Fig. 4a, Supplementary Fig. 3a)
at different segments of the brain microvasculature (Fig. 4b). The
GFP fluorescence was compatible with the imaging of the nano-
particles with no significant overlap between the fluorescence
emission spectra (Fig. 4c). Noteworthy, we found that the nano-
particles associated to the BEC predominantly at higher (3+)
branching orders of capillaries, exemplifying the heterogeneity of
the BBB even among vessels of the same category (Fig. 4d).
At 2 h post-injection, TfR-targeted nanoparticles exhibited a
non-uniform distribution in relation to the vessel wall, appearing
to be internalized or to adhere to the luminal surface of the
endothelium (Fig. 4e). For each analyzed vessel, we aligned the
imaging plane with the vessel’s long symmetry axis and extracted
the fluorescence profiles of the nanoparticles and the correspond-
ing endothelium (Fig. 4e). As a measure of separation between
nanoparticles and BECs, we used the distance between fluores-
cence peaks (Δp) given in standard deviations of the nanoparticle
fluorescence spread (σ= 0.29 µm, Fig. 1j). We categorized
nanoparticles as adhering, internalized, and abluminal with the
remaining nanoparticles belonging to an unresolved fraction at
the luminal or abluminal side of vascular endothelium (see
“Methods”), and tested our boundary conditions by visual
inspection of the images (Fig. 4f). Given a wide point spread
function along the Z-axis (depth), we refrained from analyzing
capillaries because of their small circumference. The internalized
fractions equaled 52.4%, 45.7%, and 45.4% of total nanoparticles
at the BEC for main pial venules, pial venules, and ascending
venules, respectively (Fig. 4f). The corresponding adhering
fraction of nanoparticles was 23.6%, 30.3%, and 32.5%. Since
nanoparticles located further toward the abluminal side than
internalized nanoparticles had also been endocytosed by BEC at
some point, the total fraction of sequestered nanoparticles was
64.2%, 54.6%, and 50.9% for main pial, pial, and ascending
venules, respectively (Fig. 4f). Next, we calculated high and low
estimates of internalized vs. adhering nanoparticles ratio, where
high estimates counted all unresolved luminal nanoparticles as
internalized, and low estimates counted all unresolved luminal
nanoparticles as adhering nanoparticles (Fig. 4g). In both cases,
and for all vessel types, the ratio was >1, suggesting that at 2 h
post-injection, the majority of the nanoparticles recruited to the
vessel walls were internalized by the BECs. Noteworthy, both high
and low uptake estimates increased with the venule diameter.
Nanoparticle movement dynamics. Having established that the
majority of the vessel-resident nanoparticles were internalized into
BECs, we subsequently characterized the dynamics of intracellular
nanoparticle trafficking. Once internalized, the nanoparticles
exhibited a relatively high degree of motility (Fig. 5a, Supple-
mentary Movie 4). Nanoparticles were tracked 2–3 h post-
injection throughout 30 min of continuous imaging (Δt between
frames= 30 s) in vessels with the long symmetry axis aligned with
the imaging plane (Fig. 5b, Supplementary Movie 5). To keep the
number of nanoparticles per vessel segment consistent, we selected
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the 10 most motile nanoparticles that remained in the imaging
plane from each analyzed vessel segment. The traces were aligned
to the point of origin (Fig. 5c), and to avoid underestimation of
movement in planar (x,y) coordinates, especially in vessels with a
small circumference, we projected each trace to a vector V aligned
with a vessel symmetry axis and blood flow direction, both
independent from the vessel curvature (Fig. 5c). To avoid
underestimation of the movement along the vessel v axis, we
omitted ascending venules because of their high-angle orientation












































































1 μm 1 μm 1 μm 1 μm 1 μm










Fig. 2 Robust association of nanoparticles to the BBB. a–e Two-photon in vivo images of RI7-L-A550 nanoparticles (red) 2 h after injection into the
circulation. Co-injected FITC-dx (green) delineates vessel lumen. Nanoparticles readily associate to vessel walls at pial venules, ascending venules, post-capillary
venules, and capillaries. f In contrast to venules and capillaries, nanoparticles do not associate to arterial branches of the brain microvasculature. g Co-injection
of both RI7-L-A550 and RI7-L-A488 reveals discrete punctae of both variants of nanoparticles at the vessel walls. h Time-lapse images of laser-extravasated
nanoparticles in brain parenchyma. The presence of merged fluorescence signal is because of the fluorescence signal overlap when nanoparticles are in
proximity to each other (arrowhead) and not due to nanoparticle fusion or exchange of fluorophores. All panels: pV pial venule, ascV ascending venule, pcV
post-capillary venule, cap capillaries, penA penetrating arteriole, pA pial arteriole. ‘zs’ inset indicates Z-stack maximum intensity projection.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-24323-1 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:4121 | https://doi.org/10.1038/s41467-021-24323-1 | www.nature.com/naturecommunications 5
Despite anatomical differences between pial venules and
capillaries (Fig. 4a, b, Supplementary Fig. 3a), the average total
distance traveled by the nanoparticles did not differ between these
vessel segments. However, for both pial venules and capillaries, it
was ~20% shorter (~1 µm/30 min) compared to the post-capillary
venules (Fig. 5d). This movement was unaffected by the direction
of blood flow, as in all vessel types, the median displacement
relative to the blood flow direction approximated 0 (Fig. 5e).
Noteworthy, nanoparticles exhibited movement even in capil-
laries with stalled blood flow (Supplementary Movie 6). Thus,
neither differences in cell size and blood flow velocities at distinct
vascular segments26 nor blood flow direction influenced the
intracellular movement of nanoparticles.
To assess whether the intracellular trafficking of nanoparticles
occurs by random movement (e.g., diffusion), we performed a
mean squared displacement (MSD) analysis of trajectories along
the vessel axis v (Fig. 5f). The nanoparticles exhibited significant
deviation from linearity regardless of the vessel type. This
indicated that the nanoparticle movement was inconsistent with
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present in capillaries and post-capillary venules, where MSDv(Δt)
exceeded values predicted by normal diffusion (linear fit), but was
not apparent in pial vessels that exhibited an anomalous average
trace. Although the MSD analysis does not disclose the under-
lying biological background, it suggested that the internalized
nanoparticles do not move randomly but rather via coordinated
intracellular trafficking both in capillaries and post-capillary
venules.
Nanoparticles distribute to endothelial perinuclear areas in
venules but not in capillaries. Next, we analyzed the subcellular
distribution of internalized nanoparticles. The nanoparticles
localized over time to the perinuclear region of BECs in venules
(Fig. 5g), but this was not observed in capillaries (Fig. 5h). We
quantified the spatial distribution of nanoparticles 3 h post-
injection in venules by measuring their Euclidean distances from
the geometric center of the nucleus (Fig. 5i). We refrained from
measurements in capillaries because of systematic under-
estimation of nanoparticle distances from the nucleus due to high
vessel curvature. Our data shows that the highest probability for
finding a nanoparticle in venules was at distances of 0.5–2.5 µm
from the nucleus boundary, and with numbers decreasing at
intermediate (2.5–5 µm) and distal (>5 µm) regions (Fig. 5j, k).
We observed no clustering of nanoparticles at the endothelium
perimeter (Fig. 5l), indicating that nanoparticles do not wedge
between adjacent endothelial cells, or stall in the cytosol areas
with dense cytoskeleton elements that support cell contact sites.
Lack of perivascular space impedes nanoparticle brain transit.
The possibility of nanoparticle transcytosis across the BBB is still
disputed, especially for high-affinity binding to the TfR27–31.
Here, in contrast to capillaries, nanoparticles in venules exhibited
clearly observable translocation toward the brain with distances
exceeding the endothelial thickness (Fig. 6a). Our imaging
revealed the occurrence and dynamics of transcytosis, where
nanoparticles, which associated to the venule walls, slowed down,
but once transcytosed, they rapidly progressed in the perivascular
space (Fig. 6b, Supplementary Movie 7) and further into the brain
(Fig. 6c, Supplementary Movie 8).
Given that capillaries are devoid of perivascular space17,25,
and the transcytosis-mediated entry to the brain occurred in
venules, we tested whether the lack of perivascular space
impedes nanoparticle movement at the abluminal side of
capillaries in comparison to post-capillary venules. We laser-
extravasated nanoparticles from the bloodstream at capillaries
and venules. Following extravasation, the nanoparticles in
proximity to venules rapidly migrated from the imaging plane,
consistent with the movement observed after transcytosis. In
contrast, the nanoparticles extravasated at capillaries exhibited
severe movement impairment and appeared stationary (Fig. 6d,
Supplementary Movie 9). Both the total distance traveled and
displacement of nanoparticles were significantly higher in the
brain tissue surrounding venules than capillaries (Fig. 6e). This
suggests that the lack of perivascular space impedes the
movement of nanoparticles on the abluminal side
of the capillaries.
Of note, we also detected rare events where blood-borne cells,
which had sequestered the circulating nanoparticles, crossed the
BECs and entered the perivascular spaces of the venules
(Supplementary Movie S10), consistent with the location of
immune-cell trafficking in the brain17.
Post-capillary venules are the key locus of transcytosis-
mediated brain entry. Immunohistochemical analysis enables
the assessment of distinct brain regions, but chemical processing
of the tissue collapses perivascular spaces32,33, and obliterates
the discrete signal of nanoparticles in the brain (Supplementary
Fig. 3c), providing no accurate information on the nanoparticle
location in the perivascular space (Supplementary Fig. 3d).
Given these methodological challenges, along with the rarity of
transcytosis events and a limited span of acute imaging
experiments (~4 h), we next performed long-term two-photon
imaging on awake and movement-unrestricted mice with
chronic cranial window implants (Fig. 6f). We imaged the
somatosensory cortex in the brains of awake Tie2-GFP mice 10-
day post-surgery, then reassessed the same loci 2 days later, and
injected RI7-L-A550 into the bloodstream (Fig. 6g). Subse-
quently, we imaged the animals again 30 min post-injection to
ensure that the endothelium remained structurally intact and
examined the same region at 1 and 2 days post-injection
(Fig. 6g). At 1 day post-injection, the animals exhibited
transcytosed nanoparticles at the abluminal side of the
endothelium at venules, with no significant nanoparticle
presence in the brain in proximity to capillaries (Fig. 6g). The
amount of nanoparticles in the brain decreased between 1 and
2 days post-injection, but was still apparent, indicating high
retention (Fig. 6g, h). In contrast to RI7-L-A550, the stealth
(non-targeted) nanoparticles were absent in the brain parench-
yma, indicating no passive entry of nanoparticles across the BBB
to the brain (Supplementary Fig. 4).
To quantify the distribution of nanoparticles, we measured the
distances of individual nanoparticles from the nearest vessel,
considering the vessel type and diameter. To avoid under-
estimating a nanoparticle distance from a vessel wall, we only
counted the nanoparticles located at the imaging plane aligned to
Fig. 3 Nanoparticle association density and kinetics differ between capillaries and venules. a The difference between RI7-L-A550 (red) and FITC-dx
(green, vessel lumen) fluorescence signal shows the fraction of RI7-L-A550 nanoparticles that are non-circulating and are associated to vessel walls (RI7-
L-A550nc, cyan). Non-circulating nanoparticles contour vessel boundaries in venules and capillaries, and are absent in arterioles. b 3D reconstruction of
the signal from nanoparticles associated to endothelium 2 h post-injection in vivo. The recruited (non-circulating) nanoparticles (RI7-L-A550nc, cyan) are
superimposed on the signal from nanoparticles circulating in the bloodstream (gray). The signal from RI7-L-A550nc (cyan) shows a spatially
heterogeneous association of nanoparticles across the vascular interface in the living brain. c Nanoparticles distribution 2 h post-injection showing
preferential association of nanoparticles to capillaries (yellow). Each point represents a single vessel. Nanoparticle surface density= number of
nanoparticles per µm2 vessel wall area. Blue areas demark clusters of vessels of the same type. Dashed line demarks lognormal distribution trendline.
n= number of vessels, where ncap= 213; npcV_ascV= 39; npV= 7; nmV= 2 across 4 mice. Inset illustrates vessel hierarchy and color-coding. d Upper panel:
hyperstack (Z-stack over time) imaging of the brain microvasculature after co-injection of RI7-L-A550 nanoparticles (red) and FITC-dx (vessel lumen,
green) into circulation. Squares indicate areas magnified in lower panels. Lower panels: time-lapse images of nanoparticle association over time to vessel
walls. See also Supplementary Movie 3. e Nanoparticles associate most rapidly to capillaries (yellow) and most slowly to pial venules (red, black). Surface
density= number of nanoparticles per µm2 vessel wall area (Supplementary Note). n= number of vessels, where ncap= 213; npcV_ascV= 39; npV= 7;
nmV= 2 across 4 mice. All panels: pV pial venule, ascV ascending venule, pcV post-capillary venule, cap capillaries, penA penetrating arteriole, pA pial
arteriole. ‘zs’ inset indicates Z-stack maximum intensity projection. Data are means ± SEM.
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the vessel’s long symmetry axis (Fig. 6j). Although the amount of
nanoparticles that co-localized with endothelium was comparable
between capillaries and venules (3.6% vs. 5.4% of the total count,
respectively), the entry of nanoparticles occurred mainly at post-
capillary and ascending venules (76.5% of the total count), with
only a small fraction of nanoparticles present in the brain in
proximity to capillaries (1.5% of a total count). Pial venules
belong to leptomeningeal vessels and, by definition, are not
considered a part of the BBB. Nonetheless, we also observed
nanoparticles in proximity to pial venules (13.0% of the total
count) but not in their endothelial cells (0% of a total count).
Overall, these results indicate that transcytosis-mediated
delivery of nanoparticles to the brain occurs almost exclusively
at venules, with a negligible contribution of capillaries (Fig. 7).
Discussion
For nearly two decades, drug delivery studies have faced meth-
odological challenges to determine how nanoparticles penetrate
the BBB and whether there are differences in how distinct brain
vessel types handle nanoparticle drug carriers. Here, we combined
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to provide direct insight into liposome nanoparticle delivery
through all stages of transport across the BBB to the brain. We
reveal that the post-capillary venules are primary mediators of
nanoparticle delivery to the brain parenchyma with negligible
contribution from capillaries.
Although anti-TfR antibodies can cross the BBB13,34,35, there is
a fundamental disagreement as to whether the TfR-targeted
nanoparticles can also enter the brain. The claim that TfR can
mediate transcytosis of whole nanoparticles27,28,31 is met by a
conflicting view, where delivery occurs via a release of cargo due
to the fusion of lipid-based nanoparticles with the endothelial
membrane29. Here, we provide direct evidence of TfR-mediated
transcytosis of nanoparticles across the endothelial cells and their
subsequent transit in the brain parenchyma.
The current mechanistic understanding of endothelial trans-
port comes primarily from in vitro BBB culture models, which do
not preserve vascular segment heterogeneity and do not reflect
well the molecular landscape of BECs in vivo. Only recently, the
aspect of brain microvascular zonation was explored at the level
of receptor protein expression36, transcriptomics37–39, and
transport modulation40. We show that the binding of nano-
particles to the endothelium was non-uniform and rapidly
declined along the capillary to venule axis, consistent with TfR
distribution at the level of the receptor protein from early
studies41,42 and recent complementary data to single-cell
transcriptomics37. TfR is a recycling receptor with ~10% of the
total receptor pool present at the surface of BECs43. This level of
surface available receptors was sufficient to maintain steady and
ongoing recruitment of TfR-targeted nanoparticles to the vessel
wall without saturation even at the high densities in capillaries.
Although recent gene expression analyses revealed the presence of
TfR mRNA (TFRC transcript) in arterioles37,39, we detected no
nanoparticles at this vascular segment. One intriguing possibility
is that if the TFRC transcript is present in arterioles and is
translated to the receptor protein, this pool of TfR may be
functionally excluded from the uptake of nanoparticles from the
bloodstream. An important consideration is what other BEC
features along the vascular segments might affect the nanoparticle
binding to TfR. Given that brain vasculature hemodynamics
differs between arterioles, capillaries, and venules26,44, it is plau-
sible that the slowest blood velocity in capillaries may increase the
time of interaction of nanoparticles with TfR, thus increasing the
probability of nanoparticle binding. However, we observed no
preferential association of nanoparticles at branching points or at
vessels with high tortuosity, and no increase in binding of
nanoparticles when blood-borne cells were temporarily
obstructing the nanoparticles flow. Thus, although blood pres-
sure, flow, and velocity might influence binding, they may not
play a decisive role in nanoparticle distribution, which follows
more closely the vascular gradient of TFRC expression37–39.
Conversely, the colloidal glycocalyx at the BEC luminal side may
repel negatively charged nanoconstructs or potentially bury
macromolecules within its matrix, hereby impairing
endocytosis45,46. Indeed, we detected that the internalization of
nanoparticles was not an all-or-nothing phenomenon, with at
most half of the total nanoparticles recruited from the blood
circulation being restricted to the luminal side of BEC. Although
enzymatic shedding of glycocalyx does not improve BEC uptake
of positively charged nanoparticles45, we cannot exclude that
glycocalyx might affect binding or uptake of negatively charged
particles, such as the nanoparticles used herein.
A key question is why the highest association of nanoparticles
in capillaries did not translate to the vascular location of the
highest nanoparticle brain entry. This question can be approa-
ched from two sides; one where nanoparticle transcytosis in
capillaries is negligible compared to post-capillary venules, and
one where following transcytosis, the entry of nanoparticles to the
brain at capillaries is impaired due to the absence of a
perivascular space.
Regarding transcytosis, our data suggest that its incidence had
to be low compared to post-capillary venules. Despite the highest
binding of nanoparticles to capillaries and high retention of
nanoparticles in the brain parenchyma, there was no significant
nanoparticle presence at capillary walls at 24 and 48 h post-
injection compared to post-capillary venules. Had the transcytosis
occurred to a similar degree in all vessel segments, a larger
nanoparticle fraction would be associated with the capillaries.
Else, the transcytosed nanoparticles at capillaries would have to
be re-uptaken into the BEC and further processed by lysosomes
or released into the blood, similar to previously proposed
mechanisms16. It is unlikely that nanoparticles were transcytosed
at capillaries and were subsequently relocated along the capillary
wall into the perivascular space of venules by the interstitial fluid
flow because the hydraulic resistance around the capillaries is too
high for interstitial fluid flow47. The negligible presence of
nanoparticles at capillaries also cannot be explained solely by
impaired dissociation of antibody-functionalized nanoparticles
from TfR during exocytosis11,35, as nanoparticles would also be
nearly absent at venules. Instead, the difference in trafficking
between capillaries and venules observed herein may be closely
associated with normal vessel function. It is well established that
transendothelial transport of endogenous protein receptor ligands
(or antibody-based medicines) occurs at the capillary level1.
Conversely, post-capillary venules mediate transendothelial
transport of immune cells surveilling the brain17. It could be
speculated that venular endothelial cells may contain intracellular
machinery that can better handle large entities like the nano-
particles used in the study.
Fig. 4 Most associated nanoparticles are taken up by the endothelium. a Z-stack projection of the brain cortical microvasculature endothelium imaged in
Tie2-GFP mice in vivo. b Distinct morphology of brain endothelial cells at different vascular segments in vivo. Note the clear presence of cell contact sites
and bright nuclei. c Examples of simultaneous imaging of brain endothelium (green) with RI7-L-A550 nanoparticles (red) 2 h after injection into the
circulation. d Nanoparticles associate predominantly to high branching order capillaries. e Square panels: A fraction of nanoparticles is restricted from
entering the brain endothelium and reside on the luminal side. Right panel: example of nanoparticles (red) at two distinct locations (I., II.) in relation to the
endothelium (Tie2-GFP, green). Dashed lines indicate the axes of fluorescence profiles in the lower panel. Lower panel: fluorescence profiles of
nanoparticles with low (I.) and high (II.) signal overlap with endothelium. Δp demarks nanoparticle and endothelium signal peaks separation. f Upper row:
Examples of nanoparticle classification based on Δp. Numbers at arrowheads represent Δp in σ units (σ= 0.29 µm). Lower graph: percentage distribution
of adhering (adh.), internalized (int.), unresolved at luminal (unL) or abluminal side (unA) nanoparticles, and nanoparticles found at the abluminal side of
the endothelium (abl.). Values over horizontal lines are the sum of underneath bins. n= number of nanoparticles, where nmV= 217; npV= 449; nascV= 348
across 5 mice. Inset illustrates vessel hierarchy and color-coding. g Nanoparticle uptake estimates with high and low estimate counting all unresolved
nanoparticles on luminal side (unL) as internalized (int.), or as adhering (adh.) nanoparticles, respectively. All panels: Image insets denote the position of
the imaging plane relative to a vessel perimeter. ‘zs’ inset indicates Z-stack maximum intensity projection. pV pial venule, ascV ascending venule, pcV post-
capillary venule, cap capillaries, pcA pre-capillary arteriole, penA penetrating arteriole, pA pial arteriole.
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Regarding perivascular spaces, the microanatomy of the tissue
surrounding microvessels may be the next factor influencing the
successful nanoparticle delivery into the brain. Large and post-
capillary venules are surrounded by perivascular spaces located
between the endothelial basement membrane and astrocyte glia
limitans. In contrast, capillaries are devoid of perivascular space
and are in direct contact with the brain parenchyma because both
basement membranes are fused17,48. This principal anatomical
feature is present in both murine and human brains49. Our laser-
extravasation data demonstrated that the nanoparticles in the
perivascular space move relatively freely, as opposed to the brain
parenchyma. This is in agreement with the perivascular space
being the route of least resistance, as recently observed for
nanoparticles after the infusion into the brain32, which may
explain why perivascular space facilitates the distribution of
therapeutics50. It is plausible that nanoparticles are more likely to
transcytose and progress to the brain via the route of the least
resistance, i.e., into the perivascular space of venules, instead of
entering the more restrictive compartment, i.e., the brain par-
enchyma at the capillary segment18,51. The presence of a peri-
vascular space may facilitate the egress of nanoparticles from the
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create a higher resistance environment impeding brain entry.
This is consistent with previous ex vivo findings of nanoparticles
being restricted from progressing further into the brain at capil-
lary segments of the brain vascular network16,52.
As such, while the explanation for the difference in nano-
particle brain entry is likely multifaceted, we suggest that these
two mechanisms are not mutually exclusive and that both
intracellular sorting and availability of a perivascular space may
independently influence the nanoparticle delivery to the brain.
Notably, in contrast to capillaries, post-capillary and pial
venules exhibited the preferential distribution of nanoparticles to
perinuclear areas. This corresponded to the location of both late
endosomes, and lysosomes downstream in the trafficking
route53,54, which suggests that most nanoparticles converge with
the lysosomal degradation pathway55, similarly to high-affinity
antibodies and nanoparticles targeting TfR56,57. However, a
fraction of perinuclear nanoparticles might also undergo endo-
somal recycling, typically located in proximity to the microtubule
organizing center, at the spot close to the nucleus membrane53,58.
This supports the notion that despite segmental differences in
RMT dynamics, the microanatomy of the brain surrounding
microvessels may play a decisive role in the successful brain entry
of nanoparticles.
Liposome nanoparticle formulations tested for drug delivery
range between 50 and 275 nm59. The size is known to affect, e.g.,
the nanoparticle uptake in a tissue-dependent manner60, and it is
likely that it may affect intracellular sorting during transcytosis
and subsequent migration and distribution in the brain par-
enchyma. However, the sheer size may not be the sole determi-
nant of the efficacy of nanoparticle delivery, as other parameters
that go along with the changes in size may be of importance, e.g.,
nanoparticle rigidity which is related to its lipid composition (i.e.,
saturated vs. non-saturated lipids ratio)61. The major concern of
nanoparticle-based drug delivery systems is the ability of trans-
cytosed nanoparticles to progress further in the brain par-
enchyma within the extracellular space (ECS). Most transcytosed
nanoparticles in our study were observed in perivascular areas,
even after 48 h post-injection, which indicates high perivascular
retention. However, we also observed nanoparticles at distances
from post-capillary venules corresponding to the location of
neuropil, indicating successful passage into the ECS. In vivo
diffusion experiments estimate the ECS to be in the range of
38–64 nm62, although recent super-resolution imaging revealed
ECS clefts of ~100 nm63. These dimensions may not restrict the
movement of large proteins, such as antibodies, but may preclude
the significantly larger nanoparticles from entering and progres-
sing within the ECS62,64. How ~130 nm nanoparticles traveled
within the ECS is unclear, but studies performed in human and
rat brain tissue ex vivo as well as in living brains of mice in vivo
show the process to be highly dependent on the level of
PEGylation64.
Improvements of the transport efficiency might be obtained by
re-designing the nanoparticles to comply with the notion that
low/intermediate affinity or avidity binding to receptors at the
BBB is superior to the high-affinity antibody-based transport used
in this study. While this concept was primarily investigated for
antibody transport across the BBB, new evidence suggests that it
may also impact nanoparticle transport based on targeting of the
TfR21,22, or other well-known brain drug delivery targets65. This
has uncovered an important role of sorting tubules and the
protein regulator of membrane curvature, syndapin-2, in BEC
transcytosis65, which will likely define a novel path for future
brain drug delivery strategies. Nanoparticles are presumably less
effective than antibodies concerning the brain entry but can
encapsulate a significantly larger amount of drugs with various
biochemical properties9–11. Therefore, they represent an impor-
tant avenue for therapeutics, with a large number of preclinical
evaluations and ongoing clinical trials8,12,13, and liposomes
mono-targeted to TfR outperform other RMT delivery targets in
the brain30. Nonetheless, our findings may also be of special
relevance for other targets explored for RMT-mediated nano-
particle drug delivery. For instance, the folate receptor (Folr1),
despite low expression levels, may be better suited for nano-
particle delivery, being present predominantly in venules, than,
e.g., lactoferrin receptor (Ltf) being expressed almost
exclusively in capillaries37. Furthermore, while TfR is most
abundant in capillaries, the recent single-cell transcriptomic
analysis revealed a gradient of various BBB transporters along the
vascular tree, with sparse presence in arterioles, and the highest
fraction in venules, supporting the notion that venules may be in
general more predisposed to mediate transcytosis than other
vascular segments36.
In contrast to parenchymal microvessels, the vasculature in the
dura does not form the BBB17,66. Contrary to a recent study67, we
detected no TfR-targeted nanoparticles in the dura. However, we
did observe blood-borne immune cells that infiltrated the brain
while carrying nanoparticles that were hijacked from the blood-
stream, and this immune cell infiltration occurred exclusively in
venules. Thus, a fraction of nanoparticles could also enter the
CNS in a manner independent of the BBB RMT. The leakage of
Fig. 5 Vascular differences in nanoparticle motility and subcellular distribution. a Time-lapse imaging of the vessel wall surface (left panel) and across
the vessel (right panel). Arrowheads indicate moving nanoparticles. See also Supplementary Movie 4. b Nanoparticle tracking. Left panel: circles outline
selected nanoparticles. Middle panel: nanoparticle movement during 30min of continuous imaging. Right panel: isolated movement traces (black) with
contours delineating microvessels (gray). See also Supplementary Movie 5. c Upper left inset: vessel hierarchy and color-coding. Lower left inset:
translation of nanoparticle movement from (x,y) to a (v) coordinate aligned with the vessel long symmetry axis and direction of the blood flow. Right
panels: Nanoparticle traces in (x,y) and corresponding (v) coordinate. v > 0 indicates the movement along, and v < 0 against the blood flow direction.
d Nanoparticles traverse longer distances in post-capillary venules (orange), compared to pial venules and capillaries (red, yellow; *p= 0.0302, ****p <
0.0001, respectively; two-tailed t-tests with Bonferroni post hoc correction). Time span= 30min. Data are means ± SEM. e Blood flow direction does not
affect the nanoparticle displacement. Boxplots show medians with IQR, whiskers extend between 5th and 95th percentile range. f Deviation of MSDv(Δt)
from linearity indicates movement inconsistent with diffusion predicted by the linear fit (all groups ****p < 0.0001, Wald–Wolfowitz runs test). Data are
means ± SEM. c–f n= number of nanoparticles, where npV= 90; npcV= 200; ncap= 380 across 5 mice. g In venules, nanoparticles distribute preferentially
to perinuclear areas. Images collected 3 h post-injection. h Capillaries do not exhibit a preferential perinuclear distribution of nanoparticles. i Measurement
of nanoparticles location in relation to nucleus perimeter 3 h post-injection. j Kernel density map of nanoparticle distribution in relation to the geometric
center of the nucleus. Kernel= 2σ (=0.58 µm). The heat-map represents the probability of nanoparticle presence at a given coordinate. k Percentage
distribution of nanoparticles in relation to nucleus perimeter. Non-classified are nanoparticles overlapping with the nucleus. j, k n= 3534 nanoparticles
across 5 mice. l Nanoparticles do not distribute to the endothelial cells boundaries or contact sites (dashed lines). All panels: Image insets denote the
imaging plane in relation to a vessel perimeter. pV pial venule, pcV post-capillary venule, cap capillary, nuc nucleus, MSDv(Δt) mean squared displacement
in (v) coordinate.
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large blood-borne macromolecules can reportedly occur via
wedging of leukocytes between endothelial cells in venules but not
in capillaries68. However, this phenomenon is associated with
autoimmune reactions68, and our data showed no clustering of
nanoparticles at BEC contact sites. Although TfR-targeted
nanoparticles entered the brain via the post-capillary vascular
segment, stalling of substantial quantities of nanoparticles in
capillaries may overburden and distort the intracellular trafficking
mechanisms in capillary endothelium13. This may be of particular
relevance regarding the safety of nanoparticle-based therapies. It
is plausible that nanoparticles stalled in capillaries, when loaded
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Fig. 6 Post-capillary venules are the key locus for transcytosis-mediated nanoparticle entry to the brain. a Nanoparticle movement is restricted to
the vessel boundary in capillaries but not in venules. b Real-time imaging of nanoparticle transcytosis to the brain. See also Supplementary Movie 7.
c Nanoparticle progression in the brain following transcytosis. See also Supplementary Movie 8. d Nanoparticle movement traces in the brain following
laser extravasation at capillaries (yellow) and venules (orange). Inset illustrates vessel hierarchy and color-coding. See also Supplementary Movie 9.
e Nanoparticles exhibit a relatively high degree of perivascular movement at venules (orange) compared to capillaries (yellow), where the nanoparticle
progression is restricted (n= 64 vs. 64 nanoparticles across 2 mice, ****p < 0.0001, two-tailed Mann–Whitney tests with Bonferroni post hoc correction).
Boxplots show medians with IQR, whiskers extend between 5–95th percentile range. f Upper drawing: Craniotomy for chronic two-photon imaging. Lower
drawing: Microscope stage with a movement-unrestricted awake animal. The objective is stationary, and the air-pressurized pad reacts reciprocally to the
mouse movement. g Long-term imaging of nanoparticle delivery to the brain parenchyma. Upper rows: Nanoparticles are transcytosed to the brain at
venular segments; Lower row: No apparent nanoparticle presence in the brain at capillaries and arterioles. h High-resolution images of nanoparticles after
transcytosis in post-capillary venules 2 days post-injection. i Measurement of nanoparticles distances (y) to the closest vessel with a given diameter (d).
j Nanoparticle distribution in the brain 2 days post-injection. Inset illustrates vessel hierarchy and color-coding. Right panel: nanoparticles distribution with
respect to the vessel type, distance from the nearest vessel, and the vessel diameter. Each point represents a single nanoparticle, n= 1256 nanoparticles
across 2 mice. Left panel: corresponding percentage distribution of nanoparticles. Dashed lines separate nanoparticles found in the brain at capillaries
(yellow), post-capillary and ascending venules (orange), and pial venules (red); from nanoparticles in the endothelium at capillaries (dark yellow), and
post-capillary and ascending venules (brown). All panels: ‘zs’ inset indicates Z-stack maximum intensity projection. pA pial artery, pV pial venule, ascV
ascending venule, pcV post-capillary venule, cap capillary.













































Fig. 7 Working model of transcytosis-mediated nanoparticle delivery to the brain. Despite the highest association to capillaries, the TfR-mediated
delivery of liposome nanoparticles occurs almost exclusively in post-capillary venules, and is negligible in capillaries, where the lack of perivascular space
impedes the progression of nanoliposomes into the brain parenchyma.
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concentrations of the payload within capillary endothelium,
exerting negative side effects on vascular function.
Last, our methodological platform allows to describe the
nanoparticles in the living brain at microscale resolution in live,
and in awake animals. It is suitable for examining the potential
effects of changes in transcytosis on large molecule therapeutics
delivery in the aged brain, recently reported to exhibit a sub-
stantial decline in RMT36; and in disease states, e.g., during
ischemia-induced imbalance in transcytosis69, reduction of peri-
vascular spaces32, or ECS changes in edema63. Our findings may
also help to avoid pitfalls in the design of drug delivery systems,
e.g., in Alzheimer’s disease, where Aβ may deposit along peri-
arteriolar, rather than venular perivascular space70.
In summary, we identified post-capillary venules as the key site
for transcytosis-mediated brain entry of nanoparticles. Our
results provide a vascular zonation map of TfR-targeted nano-
particle trafficking that may aid efforts to develop efficient and
safer therapeutic approaches. In contrast to capillaries aimed
routinely for drug design strategies, post-capillary venules as an
accessible part of the vascular segment are more apt for nano-
particle delivery across the BBB.
Methods
Animals. All animal experiments were approved by The Danish National Com-
mittee on Health Research Ethics following the guidelines established by the
European Council’s Convention for the Protection of Vertebrate Animals Used for
Experimental and Other Scientific Purposes (reference numbers: #2019-15-0201-
01655; #2019-15-0201-01658; #2016-15-0201-00920), and were in compliance with
ARRIVE guidelines. We used wild-type C57Bl/6 mice, age 5–7 months (23–31 g)
and age-matched (25–32 g) homozygous Tg(TIE2GFP)287Sato/J transgenic
reporter mice (Tie2-GFP mice, #003658, The Jackson Laboratory) expressing GFP
under the endothelial-specific receptor tyrosine kinase (Tie2) promoter71. All
animals were housed in ventilated cages under a 12 h light/12 h dark cycle, at 50 ±
10% relative humidity, at room temperature, with ad libitum access to food and
water. The animal housing facility has been accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC), and the
Federation of Laboratory Animal Science Associations (FELASA).
Animal preparation for acute imaging. Surgery was performed as previously
described, with minor modifications72. Briefly, animals were anesthetized by
intraperitoneal (i.p.) injection of xylazine (10 µg/ganimal) and ketamine (60 µg/g,
then 30 µg/ganimal, at 20–25 min intervals). A tracheotomy was performed for
mechanical respiration (180–220 μL volume at 190–240 strokes/min; MiniVent
Type 845, Harvard Apparatus) with O2-supplemented air (1.5–2 mL/min). Two
catheters were inserted, one into the left femoral artery for injection of compounds
and nanoparticles, and for monitoring mean arterial blood pressure (MABP;
Pressure Monitor BP-1, World Precision Instruments), and the other into the
femoral vein for anesthesia infusion during imaging. The animal was turned to the
prone position and the scalp was removed. The periosteum was removed with a
FeCl3-soaked cotton bud, and the exposed skull was glued (Loctite Adhesives) to a
custom-made metal head plate. A craniotomy was performed over the right
somatosensory cortex (3 mm lateral, 0.5 mm posterior to bregma; Ø= 4 mm; 4500
rpm dental drill). The bone flap was carefully lifted, the dura removed, and 1%
agarose (type III-A, Sigma-Aldrich) in artificial cerebrospinal fluid (aCSF; in mM:
NaCl 120, KCl 2.8, Na2HPO4 1, MgCl2 0.876, NaHCO3 22, CaCl2 1.45, glucose
2.55, pH= 7.4) was applied on the brain surface. An imaging coverslip (~4 × 4mm,
0.08-mm thick; Menzel-Gläser) was positioned onto the craniotomy, leaving a
~0.5-mm gap for glass microelectrode insertion. The animal was transferred to the
imaging stage, and the anesthesia was changed to continuous infusion of α-
chloralose (50 mg/kg BW per hour) via an intravenous catheter.
Mice were allowed to rest for 25 min before the imaging procedures. Prior to
imaging, a ~50 µL blood sample was collected via the arterial catheter for blood gas
evaluation (ABL, Radiometer), and the respiration rate and volume were adjusted if
necessary. To ensure physiological conditions, we monitored end-tidal CO2 levels
and MABP, and body temperature was maintained at 37 °C using a rectal
thermistor-regulated heating pad.
Animal preparation for chronic/awake imaging. The surgery was performed as
previously described, with minor modifications73. Briefly, 4 h prior to the surgery,
the animals were injected with dexamethasone (4.8 mg/g BW; Dexavit, Vital
Pharma Nordic). The anesthesia was induced with 5% isoflurane (ScanVet) in O2-
supplemented air (10%). Eyes were lubricated with eye ointment (Viscotears,
Novartis), and the animal’s head was shaved and mounted onto a stereotactic
frame. The body temperature was maintained during all steps of the surgery at
37 °C using a rectal thermistor-regulated heating pad. Surgery was performed in an
aseptic environment with heat-sterilized surgical tools.
The shaved skin was disinfected with chlorhexidine/alcohol (0.5%/74%;
Kruuse). Next, carprofen (5 mg/kg BW; Norodyl, Norbrook), buprenorphine (0.05
mg/kg BW; Temgesic, Indivior), and lidocaine (100 µL 0.5%) were subcutaneously
injected under the scalp. The anesthesia was reduced to 1.8–2.0% isoflurane, the
scalp was removed, and the bone surface was cleaned from the periosteum with an
ultrasonic drill (Piezosurgery, Mectron). A craniotomy was performed over the
right somatosensory cortex (2 mm lateral, 0.5 mm posterior to bregma; Ø= 3 mm),
the bone flap was carefully lifted, and the exposed brain temporarily covered with a
hemostatic absorbable gelatin sponge (Spongostan®, Ferrosan, Denmark) pre-
wetted with ice-cold aCSF. The cranial opening was filled with aCSF, then sealed
with an autoclave-sterilized round imaging coverslip (Ø= 4 mm, 0.17-mm thick;
Laser Micromachining LTD). The rim of the coverslip was secured with a thin layer
of Vetbond (3M Company), and a lightweight stainless steel head plate (Neurotar)
was positioned on the top of the skull in alignment with the cranial window. The
skull was coated with adhesive resin cement (RelyX Ultimate, 3M Company) to
secure the exposed bone, including the skin incision rim, and to firmly attach the
metal plate to the head. Next, the animals were transferred onto a pre-warmed
heating pad to wake from anesthesia (~5 min) in a cage supplemented with pre-
wetted food pellets for easy chow and hydration.
Post-operation care consisted of subcutaneous injections of Temgesic (3 h) and
Rimadyl (24 and 48 h post-surgery, doses as before). Animal welfare was closely
monitored during the 7 days of post-surgical recovery and subsequent imaging
training procedures. All animals underwent recurrent 30-min/day training sessions
before the imaging to gradually habituate to the mobile cage system (Neurotar)
with sugar-supplemented water as a reward (~14 days training). Given that no
catheters were mounted in chronically imaged animals, the nanoparticles were
injected retroorbitally 10 days post-surgery during brief (~2 min) isoflurane
anesthesia (5%). This administration route was preferential to, e.g., tail vein
injections, because it provided better control over the injectant volume. The
imaging sessions never exceeded 45 min.
Nanoparticle preparation. 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC),
ovine cholesterol, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy
(polyethylene glycol)-2000] ammonium salt (DSPE-PEG2k), and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000]
ammonium salt (DSPE-PEG2k-maleimide) were purchased from Avanti Polar
Lipids (Alabaster). The stealth nanoparticles were prepared to consist of DSPC/
cholesterol/DSPE-PEG2k (molar composition: 56.3:38.2:5.5), and the antibody-
functionalized nanoparticles to consist of DSPC/cholesterol/DSPE-PEG2k/DSPE-
PEG2k-maleimide (molar composition: 56.3:38.2:5:0.5). The fluorescent nano-
particles were supplemented with 0.5 mol% of 1,2-dipalmitoyl-sn-glycero-3-phos-
phoethanolamine labeled with Atto 488 (Atto 488 DPPE) or Atto 550 (Atto 550
DPPE; Atto-Tec). We chose DPPE-anchored Atto dyes because of their fairly low
dissociation rate from liposome nanoparticles in plasma74, and their high fluor-
escence quantum yield and photostability. To obtain lipid powder mixtures of the
above compositions, the constituent lipids were dissolved in tert-butanol (Sigma-
Aldrich)/Milli-Q water solution (9:1) and heated to 40–50 °C to ensure complete
dissolution. The lipid solutions were then plunge-frozen in liquid N2 and lyophi-
lized overnight to remove the solvent (ScanVac CoolSafe lyophilizer, LaboGene).
Nanoparticle fluorescent tagging. To obtain fluorescently labeled nanoparticles,
the lyophilized lipids were hydrated in 70 °C phosphate-buffered saline (PBS; 10
mM phosphate, 137 mM sodium chloride, 2.7 mM KCl, pH 7.4; tablets from
Sigma-Aldrich) to a 50 mM lipid concentration. The lipid suspensions were vor-
texed every 5 min for a total period of 30 min, then subjected to five freeze-thaw
cycles by alternate placement in a liquid N2 and a 70 °C water bath. Next, the lipid
suspensions were extruded 21 times through a 100-nm polycarbonate filter
(Whatman, GE Healthcare) at 70 °C using a mini-extruder (Avanti Polar Lipids) to
form nanoparticles.
Nanoparticle targeting. We used a high-affinity (KD= 6 nM) monoclonal anti-
TfR antibody clone RI7217 to functionalize the nanoparticles21. The antibody was
produced in-house using the hybridoma technique at Laboratory for Neurobiology,
Aalborg University, Denmark. The antibody specificity was previously determined
using surface plasmon resonance21. To functionalize the nanoparticles with either
RI7217 or a rat isotype IgG control (Thermo Fisher Scientific, Waltham, MA,
USA), we prepared solutions of 8 mg/mL antibody in borate buffer (100 mM
borate, 2 mM EDTA, pH 8.0; all Sigma-Aldrich). The antibody concentrations were
determined from the absorbance at 280 nm (NanoDrop 2000c spectrophotometer,
NanoDrop Products, Thermo Fisher Scientific) using mass extinction coefficients
of 1.3 (mg/mL)−1 cm−1 and 1.5 (mg/mL)−1 cm−1 for RI7217 and IgG isotype,
respectively, determined in a separate micro-BCA experiment. Traut’s reagent
(Thermo Fisher Scientific) was added to a reagent-to-antibody molar ratio 10:1 in
Protein LoBind tubes (Eppendorf), and the solutions were incubated for 1 h at
room temperature under constant shaking at 500 rpm. Using Amicon Ultra-4 30
kDa centrifugal filter units (Merck), we transferred the thiolated antibodies to PBS
and determined their concentration using the NanoDrop 2000c as described above.
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Next, we added 1.05 mg of newly prepared thiolated antibodies to 700 µL of newly
prepared nanoparticles (lipid concentration ~35–40 mM) in Protein LoBind tubes
and replaced the air phase in the tubes with N2. The samples were then incubated
for 24 h at room temperature under constant shaking at 500 rpm, allowing the
thiolated antibodies to couple to the maleimide groups on the surface of the
nanoparticles. The antibody-functionalized nanoparticles were separated from
unbound antibodies using a Sepharose CL-4B (GE Healthcare) size-exclusion
chromatography column eluted with PBS (dimensions, 1.5 × 20 cm; flow rate, 1
mL/min). The recovered nanoparticles were pooled in Amicon Ultra-4 100 kDa
centrifugal filter units (Merck) and concentrated by centrifuging at 2000 × g until
the lipid concentration was increased to 30–40 mM.
Nanoparticle cisplatin loading, targeting, and detection. To prepare cisplatin-
loaded nanoparticles, cis-diammineplatinum(II) dichloride (cisplatin; Sigma-
Aldrich) was dissolved in PBS to a nominal concentration of 8.5 mg/mL. The
solutions were magnetically stirred for 1 h at 70 °C and subsequently left at room
temperature for 15 min, allowing undissolved cisplatin crystals to precipitate. The
supernatants were transferred to new vials and magnetically stirred while being
heated to 70 °C. The solutions were then added to lyophilized lipids, resulting in
50 mM lipid suspensions that were magnetically stirred for 1 h at 70 °C and
extruded as described above for the fluorescently labeled nanoparticles. The sam-
ples were cooled to room temperature to allow any residual cisplatin crystals to
precipitate, and the supernatants were run on a Sepharose CL-4B size-exclusion
chromatography column eluted with PBS (dimensions 1.5 × 20 cm, flow rate 1 mL/
min) to remove free cisplatin. The recovered nanoparticles were concentrated using
Amicon Ultra-4 100 kDa centrifugal filter units by centrifuging at 2000 × g.
To prepare antibody-functionalized cisplatin-loaded nanoparticles, the
antibodies were thiolated as described above. Then, 0.5 mg of newly prepared
thiolated antibody was added to 700 µL of newly prepared cisplatin-loaded
nanoparticles (lipid concentration ~13 mM) in a Protein LoBind tube. The
nanoparticles were then incubated, recovered, and concentrated as described above
for the fluorescently labeled antibody-functionalized nanoparticles.
Brain uptake of cisplatin was measured with inductively coupled plasma mass
spectrometry (ICP-MS) as recently described22. Briefly, a maximum of 100 mg
brain tissue input was digested in 65 °C aqua regia overnight, then diluted in 0.5
ppb iridium aqueous solution (Sigma-Aldrich). Next, the samples were diluted in
2% HCl, 0.5 ppb iridium aqueous solution, and immediately analyzed using an
iCAP Q ICP-MS system (Thermo Scientific) equipped with a Cetac ASX-520
AutoSampler and a Neslab ThermoFlex 2500 chiller. Measurements were
performed in standard mode with iridium as an internal standard, and platinum
levels were determined by comparing to a platinum standard curve in the range
0.08–5 ppb (Sigma-Aldrich). The data were represented as the percent of injected
dose per gram of the brain tissue (%ID/g).
Nanoparticle properties in vitro. The phosphorus concentrations of the nano-
particle stock samples were determined using ICP-MS. The samples were diluted in
2% HCl, 10 ppb gallium aqueous solution (Sigma-Aldrich), and the measurements
were done in kinetic energy discrimination mode with gallium as an internal
standard. Phosphorus levels were determined by comparing to a phosphorus
standard curve in the range 25–100 ppb (Sigma-Aldrich). The phospholipid con-
centrations were estimated by subtracting the phosphorus background of the PBS
buffer, and the total lipid concentrations estimated by dividing the phospholipid
concentrations with 0.618, taking into account that cholesterol does not contain
phosphorus. For the cisplatin-loaded nanoparticles, we also used ICP-MS to
determine the platinum concentrations. The samples were diluted in 2% HCl, 0.5
ppb iridium aqueous solution, and the measurements were performed in standard
mode with iridium as an internal standard. Platinum levels were determined by
comparing to a platinum standard curve in the range 0.125–1 ppb. The size of the
nanoparticles (dissolved in PBS) was measured using dynamic light scattering, and
the zeta potential of the nanoparticles in phosphate-glucose buffer (10 mM phos-
phate, 280 mM glucose, pH 7.4; reagents from Sigma-Aldrich) was measured using
mixed measurement mode phase analysis light scattering (Zetasizer Nano ZS,
Malvern Instruments). The antibody conjugation level on the functionalized
nanoparticle was determined using the micro-BCA assay (reagents purchased from
Thermo Fisher Scientific), performed by incubating samples (including bovine
serum albumin [BSA] standard samples) for 1 h in a 60 °C water bath and then
transferring them to a 96-well plate to measure their absorbance at 562 nm using a
Spark multimode microplate reader (Tecan). To account for the small contribution
of lipids in the micro-BCA assay74, we also performed the micro-BCA on non-
functionalized nanoparticles, which allowed for the subtraction of the lipid con-
tribution to determine the amount of antibody conjugated to the nanoparticles.
The hydrodynamic diameter (Dh) of RI7-functionalized Atto 550-tagged (RI7-L-
A550) and Atto 488-tagged (RI7-L-A488) nanoparticles was in the range of Dh=
~135–140 nm (Supplementary Table 1) and comparable to other TfR-targeted
clinically relevant formulations57,67. Both RI7-L-A550 and RI7-L-A488 had a low
polydispersity index (≤0.13), indicating high size homogeneity. Assuming the
nanoparticles contained on average ~2.5 × 105 lipids, the conjugation level of 30 g/
mollipid corresponded to ~50 antibodies per nanoparticle74.
Fluorescent probes. FITC-dextran (MW 2 MDa, 0.5%, Sigma-Aldrich), TRITC-
dextran (MW 65 kDa, 1%, Sigma-Aldrich), or bovine serum albumin Alexa Fluor
488-conjugate (BSA-Alexa 488, 1%, Invitrogen) was administered as a single bolus
injection (50 µL) via a femoral arterial catheter. All were dissolved in sterile saline
and administered subsequently to nanoparticles. In addition to delineating a vessel
lumen, lack of extravascular leak of dyes indicated preserved BBB structural
integrity after the microsurgery.
Imaging setup. In vivo two-photon imaging was performed with an SP5 upright
laser scanning microscope (Leica Microsystems) coupled to MaiTai Ti:Sapphire
laser (Spectra-Physics). The images were collected using a 20× 1.0 NA water-
immersion objective. The fluorescence signal was split by FITC/TRITC filter and
collected by two separate multi-alkali photomultipliers after 525–560 nm and
560–625 nm bandpass filter (Leica Microsystems). The fluorophores were excited at
870 nm with the 14 mWatt output power at the sample. The images were collected
using LAS AF v. 4.4 (Leica Microsystems) in 16-bit color depth and exported to
ImageJ for further analysis (v. 1.52a; NIH). 3D reconstructions were performed via
volume rendering in Amira v. 6 (FEI Visualization Sciences Group).
Surface density calculation. To assess spatio-temporal properties of nanoparticles
association to the endothelium, we monitored the association of nanoparticles for
2 h after injection with respect to all cerebral vessel types using hyperstack (4-
dimensional) imaging. Data were recorded as a series of Z-stacks in bidirectional
scanning mode with triple frame averaging, from 387.5 μm× 387.5 μm area
(2048 × 2048 pixel resolution) and 144 μm depth span (Z-step size 2.50 μm) with
7.5-min intervals between consecutive Z-stacks. The nanoparticles were counted
from all vessels in the field of view, with each individual vessel followed over time.
The vessel surface area was calculated from vessel diameter delineated by FITC-dx
or TRITC-dx signal and the length of the vessel measured in 3D. The association
density was obtained from a nanoparticle count per corresponding vessel wall area
[nanoparticles/µm2].
Nanoparticle uptake estimation. The precise spatial localization of nanoparticles
in microscopy is non-trivial because of the diffraction limit; therefore, we defined
the boundary conditions characterizing nanoparticle location using the previously
calculated nanoparticle fluorescence signal spread, i.e., standard deviation (σ) of
Gaussian fluorescence distribution (σ= 0.29 µm; Fig. 1j). The nanoparticles were
categorized as internalized only when separated from endothelium peak signal by |
Δp| < σ, and as adhering (adh.) when separated from the endothelium peak signal
by at least 2σ, i.e., Δp > 2σ. Additional groups consisted of nanoparticles found on
the abluminal side (abl.), i.e., when Δp <−2σ; and nanoparticles that could not be
categorically classified into any of the groups above and represented the inter-
mediate groups, i.e., unresolved on luminal side (unL) when σ < Δp < 2σ; and
unresolved on the abluminal side (unA) when −2σ < Δp <−σ (Fig. 4f).
Subcellular distribution mapping. We imaged the surface of the vessels, i.e., a ~5
µm planar optical section aligned with the vessel circumference at 3 h post-
injection. When measuring distances from the nucleus geometric center to nano-
particles (ImageJ), we set the distance cut-off point to 11 µm to exclude the
nanoparticles that belonged to neighboring endothelial cells and to avoid dis-
tribution bias due to the non-concentric spindle-like geometry of endothelial cells.
In addition, we excluded nanoparticles located in line from the geometric center
toward the vessel wall, where the cut-off distance exceeded the vessel boundary. We
took this step to minimize the effect of the vessel curvature on the estimation of the
distance.
Nanoparticle tracing. Nanoparticles were manually tracked (ImageJ) 2–3 h post-
injection throughout 30 min of continuous imaging (Δt between frames= 30 s) at
the vessels with the long symmetry axis aligned with the imaging plane. To avoid
systemic differences in nanoparticle tracing experiments, we analyzed vessels
aligned with the focal plane, i.e., oriented perpendicular to the imaging axis.
Tracing nanoparticles from penetrating vessels that traversed the imaging plane
under a steep angle, e.g., ascending venules, might underestimate the movement
along the long vessel symmetry axis v. Furthermore, the nanoparticles would only
briefly appear in the imaging plane, and in order to obtain longer time recordings
(30 min), the imaging would be limited to nanoparticles that exhibited only a small
degree of movement to remain in the focal plane.
MSD analysis. To characterize the motion of nanoparticles, we used the mean
square displacement (MSD) analysis75. Time-lapse recordings were collected in
bidirectional scanning mode from 387.5 μm× 387.5 μm area (2048 × 2048 pixel
resolution) for 30 min at 30-s intervals (60 data timepoints). Each nanoparticle
trajectory was manually traced, treating the centroid of nanoparticle 2D fluores-
cence intensity as a location coordinate. The planar (x,y) trajectories were projected
to a vector V aligned with the vessel long symmetry axis v and with the direction of
the blood flow. For every trajectory, the displacements in v coordinate in time t
were extracted for each multiplier of the smallest resolved time interval d (i.e., t=
d, t= 2d, t= 3d…t= i*d), where i= 60 timepoints and d= 30 s. The
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displacements were squared and averaged between nanoparticles for each respec-
tive time interval t= i*d. The significant deviation of MSD(Δt) from linearity with
the increase of t indicates a non-stochastic (directional) movement component75.
We assessed MSDv(Δt) linearity with the least-squares linear regression fit
weighted by the inverse of data point variance, followed by Wald–Wolfowitz
runs test.
Electrophysiological recordings. Electrocortical brain activity (ECoG) was
recorded via a heat-pulled borosilicate glass electrode containing an Ag/AgCl
filament and filled with aCSF (electrode tip Ø, 2–3 μm; inner Ø, 0.86 mm; outer Ø,
1.5 mm; Sutter Instrument; resistance 1.5–2.0 MΩ). The electrode was inserted
under the glass coverslip ~50 μm into the cerebral cortex, and the reference elec-
trode was positioned in the neck muscle. The total electrical signal was filtered
(3000 Hz low-pass filter), then amplified 10× (AP311 analog amplifier; Warner
Instruments), and the alternate current-ECoG component (i.e., spontaneous brain
activity) was obtained after further 100× amplification and 0.5 Hz high-pass filter
(NL 106 analog amplifier and NL 125/126 analog filter, NeuroLog). Analog data
were digitized (Power 1401, CED) at 20 kHz. For the exhaled CO2, MABP (the raw
readout) was collected. All data were recorded in Spike2 software (v. 7.02a; CED).
Statistics and reproducibility. Following the D’Agostino-Pearson normality test,
an unpaired two-tailed Student’s t-test or two-tailed Mann–Whitney tests were used
for data with normal or non-normal distribution, respectively, unless stated
otherwise, i.e., in Fig. 5f. For multiple comparisons between groups, Bonferroni post
hoc corrections were used. The number of analyzed nanoparticles or vessel seg-
ments across the biologically independent mice is provided on figure legends and on
figures with the number of mice in brackets. All statistical analyses were performed
in Prism v.8.2 (GraphPad). Data were plotted in Prism v.8.2. or in OriginPro 2018
(OriginLab Corporation). The panels with representative images were selected from
n mice showing similar results; where: Fig. 1f nRI7-L-A550= 4, nRI7-L-A488= 4; Fig. 1h
nRI7-L-A550= 3, nRI7-L-A488= 3; Fig. 1i n= 1; Fig. 2a–f n= 7; Fig. 2g, h n= 1; Fig. 3a,
b n= 4; Fig. 3d n= 4; Fig. 4a–e n= 5; Fig. 5a, b n= 5; Fig. 5g–i, l n= 5; Fig. 6a
nupper_panel= 4, nlower_panel= 3; Fig. 6b n= 3; Fig. 6c n= 2; Fig. 6d n= 4; Fig. 6g, h
n= 2; Supplementary Figs. 1a, c nRI7-L-A550= 6, nRI7-L-A488= 5; Supplementary
Fig. 1d n= 2; Supplementary Fig. 2a–d n= 2; Supplementary Fig. 3a n= 5. Sup-
plementary Fig. 3b–e n= 2. Images from single experiments were included to
illustrate the lack of targeting properties of nanoparticles without TfR-targeting
antibody, i.e., in Supplementary Fig. 1f, g n= 1; Supplementary Fig. 1h, i n= 1;
Supplementary Fig. 2e n= 1; Supplementary Fig. 4 n= 1 mice.
Exclusion criteria. Prior to injection of nanoparticles, all animals with abnormal
blood pressure (<50 mmHg), abnormal brain ECoG activity, or significant (>2 µm/
min) brain movement in x, y, or z coordinates were excluded from the study (3
excluded out of total 36 animals for in vivo imaging). No animals were excluded
from immunohistochemistry analysis (total= 2 mice injected with RI7-L-A550 for
confocal imaging) and from ICP-MS (total= 13 mice).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available within the article and
its Supplementary Information files or from the corresponding author upon reasonable
request. Source data are provided with this paper.
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